Shamburg News · 8-K filed Oct 19, 2026, 9:06 AM EDT

Veradermics Reports Positive Topline Phase 3 Study 304 Results for VDPHL01 in Male Pattern Hair Loss

MANE · Veradermics, Inc

  • Other event
  • Reg FD disclosure
  • Materiality: high

On October 19, 2026, Veradermics, Incorporated announced positive topline data from Phase 3 Study '304' evaluating VDPHL01 in 536 males with mild-to-moderate pattern hair loss. The trial met all primary and secondary endpoints, with mean non-vellus hair count increases of 28.6 hairs/cm² (QD) and 36.4 hairs/cm² (BID) versus 6.6 hairs/cm² for placebo at Month 6. The company reported no treatment-related serious adverse events and no cardiac-origin adverse events of special interest, and furnished the press release and investor presentation as Exhibits 99.1 and 99.2.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001827635-26-000036.

Written from the filing by Shamburg Markets. Figures are as reported by the company.